Scarica l'app Stockscreener
21.42
2.32%
0.47
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché RARE Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$20.95
Aprire:
$20.97
Volume 24 ore:
510.43K
Relative Volume:
0.18
Capitalizzazione di mercato:
$2.10B
Reddito:
$672.72M
Utile/perdita netta:
$-575.44M
Rapporto P/E:
-3.6703
EPS:
-5.8361
Flusso di cassa netto:
$-487.00M
1 W Prestazione:
+7.99%
1M Prestazione:
-8.35%
6M Prestazione:
-28.52%
1 anno Prestazione:
-36.65%
Intervallo 1D:
$20.92
$21.48
Intervallo di 1 settimana:
$19.10
$21.48
Portata 52W:
$18.29
$42.37
Ultragenyx Pharmaceutical Inc Stock (RARE) Company Profile
Nome
Ultragenyx Pharmaceutical Inc
Settore
Industria
Telefono
415-483-8800
Indirizzo
60 LEVERONI COURT, NOVATO, CA
Compare RARE vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RARE
Ultragenyx Pharmaceutical Inc
|
21.41 | 2.06B | 672.72M | -575.44M | -487.00M | -5.8361 |
VRTX
Vertex Pharmaceuticals Inc
|
451.39 | 113.44B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
776.16 | 81.68B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
749.84 | 45.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.66 | 43.88B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.56 | 35.25B | 606.42M | -1.28B | -997.58M | -6.403 |
Ultragenyx Pharmaceutical Inc Stock (RARE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-24 | Downgrade | Goldman | Buy → Neutral |
| 2025-10-20 | Iniziato | Wells Fargo | Overweight |
| 2025-07-28 | Ripresa | H.C. Wainwright | Buy |
| 2025-05-28 | Iniziato | William Blair | Outperform |
| 2024-06-06 | Aggiornamento | Goldman | Neutral → Buy |
| 2024-04-22 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-12-08 | Iniziato | Wells Fargo | Overweight |
| 2023-06-14 | Ripresa | Credit Suisse | Outperform |
| 2023-06-06 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2023-04-26 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-01-18 | Ripresa | Canaccord Genuity | Buy |
| 2022-12-30 | Ripresa | H.C. Wainwright | Buy |
| 2022-11-03 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2022-10-13 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2022-08-01 | Downgrade | Evercore ISI | Outperform → In-line |
| 2022-03-16 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2022-02-11 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2021-09-30 | Iniziato | H.C. Wainwright | Buy |
| 2021-08-19 | Iniziato | UBS | Sell |
| 2021-07-15 | Iniziato | Guggenheim | Neutral |
| 2021-06-29 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2021-06-04 | Ripresa | Robert W. Baird | Neutral |
| 2021-05-06 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-05-06 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2021-04-26 | Ripresa | Credit Suisse | Neutral |
| 2021-03-02 | Ripresa | Stifel | Buy |
| 2021-02-12 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-12-07 | Downgrade | Wedbush | Outperform → Neutral |
| 2020-11-24 | Ripresa | Evercore ISI | In-line |
| 2020-11-12 | Downgrade | BofA Securities | Buy → Neutral |
| 2019-08-02 | Ripresa | Wedbush | Outperform |
| 2019-03-27 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2019-02-22 | Ripresa | Raymond James | Outperform |
| 2019-01-02 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2018-11-08 | Aggiornamento | Citigroup | Sell → Neutral |
| 2018-09-10 | Iniziato | Morgan Stanley | Equal-Weight |
| 2018-06-21 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2018-05-11 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2018-05-10 | Iniziato | Goldman | Neutral |
| 2018-04-18 | Aggiornamento | SunTrust | Hold → Buy |
| 2018-03-22 | Ripresa | Piper Jaffray | Overweight |
| 2018-02-21 | Reiterato | Stifel | Buy |
| 2018-01-22 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2018-01-18 | Iniziato | Credit Suisse | Outperform |
| 2017-12-05 | Reiterato | Barclays | Equal Weight |
| 2017-12-04 | Aggiornamento | Jefferies | Hold → Buy |
| 2017-09-14 | Aggiornamento | Wedbush | Neutral → Outperform |
Mostra tutto
Ultragenyx Pharmaceutical Inc Borsa (RARE) Ultime notizie
Ultragenyx (RARE) Shares Positive Results From DTX301 Phase 3 Study - Yahoo Finance
Ultragenyx Pharmaceutical Inc. Notice of April 6, 2026 Application Deadline for Class Action ... - caledonianrecord.com
Ultragenyx Pharmaceutical Inc. Notice of April 6, 2026 Application Deadline for Class Action Lawsuit - GlobeNewswire Inc.
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Mereo BioPharma Group plc of Class Action Lawsuit and Upcoming Deadlines – MREO - GlobeNewswire Inc.
Ultragenyx Pharmaceutical Reports FDA Acceptance of IND Application for UX016 - Bitget
Ultragenyx Pharmaceutical (NASDAQ:RARE) Trading Up 8.7%Still a Buy? - MarketBeat
RARE Shareholder Alert: Ultragenyx Pharmaceutical Inc. Securitie - GuruFocus
Ultragenyx Pharmaceutical Announces FDA Acceptance of UX016 IND - Yahoo Finance
Holzer & Holzer, LLC Reminds Investors of April 6, 2026 Lead Plaintiff Deadlines in Shareholder Class Action Lawsuits Against Mereo BioPharma Group plc (MREO), POMDOCTOR LIMITED (POM), and Ultragenyx Pharmaceutical Inc. (RARE) - lincolnjournal.com
RARE Deadline: RARE Investors with Losses in Excess of $100K Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit - themalaysianreserve.com
Portnoy Law Firm Announces Class Action on Behalf of Ultragenyx Pharmaceutical, Inc. Investors - GlobeNewswire
Patient-Funded UX016 IND Clearance Might Change The Case For Investing In Ultragenyx Pharmaceutical (RARE) - Yahoo Finance
Ultragenyx Stock Gaps Down 5% Amid Weak Start and Market Concerns - Markets Mojo
Ultragenyx (RARE) Gains FDA Clearance for New Drug UX016 - GuruFocus
Investors in Ultragenyx Pharmaceutical Inc. Should Contact - GlobeNewswire
POM IMPORTANT DEADLINE: ROSEN, LEADING TRIAL ATTORNEYS, Encourages PomDoctor Ltd. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 7 Deadline in Securities Class Action - GlobeNewswire Inc.
RARE FINAL DEADLINE: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Ultragenyx Pharmaceutical ... - caledonianrecord.com
RARE FINAL DEADLINE: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Ultragenyx Pharmaceutical Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 6 Deadline in Securities Class Action - GlobeNewswire Inc.
NASDAQ: RARE CLASS ACTION NOTICE - marketscreener.com
Ultragenyx gains FDA IND clearance of UX016 for GNE myopathy - MSN
Ultragenyx Investors Urged to Join Securities Fraud Lawsuit - National Today
Ultragenyx Wins FDA IND Clearance for UX016 Therapy - TipRanks
Ultragenyx Announces FDA Clearance of IND for UX016 to Treat GNE Myopathy - Minichart
Ultragenyx Pharmaceutical Inc. Announces FDA Clearance Of Investigational New Drug Application For Ux016, A Sialic Acid Prodrug For The Treatment Of GNE Myopathy - marketscreener.com
Ultragenyx (RARE) wins FDA IND clearance, plans UX016 Phase 1/2 GNE myopathy trial - Stock Titan
Ultragenyx Announces FDA Clearance of Investigational New Drug (IND) Application for UX016, a Sialic Acid Prodrug for the Treatment of GNE Myopathy - The Manila Times
Rare muscle disease with no approved drugs gets a new trial - Stock Titan
Ultragenyx downgraded to neutral at Goldman Sachs on setrusumab data - MSN
Assenagon Asset Management S.A. Has $4.59 Million Holdings in Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire
INVESTOR ALERT: Ultragenyx Pharmaceutical Inc. (RARE) Investors with Substantial Losses Have Opportunity to Lead Securities Class Action LawsuitRGRD Law - The Daily Tribune News
RARE DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Ultragenyx Investors of Securities Class Action Deadline on April 6, 2026 - PR Newswire
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) Q4 2025 earnings call transcript - MSN
Is It Time To Reconsider Ultragenyx Pharmaceutical (RARE) After Its Prolonged Share Price Slump? - Sahm
[ARS] Ultragenyx Pharmaceutical Inc. SEC Filing - Stock Titan
Ultragenyx (NASDAQ: RARE) seeks approval for 2026 equity plan and director slate - Stock Titan
ULTRAGENYX DEADLINE: ROSEN, TOP-RANKED INVESTOR COUNSEL, Encourages Ultragenyx Pharmaceutical ... - caledonianrecord.com
ULTRAGENYX DEADLINE: ROSEN, TOP-RANKED INVESTOR COUNSEL, - GlobeNewswire
Vanguard disaggregates Ultragenyx holdings (NASDAQ: RARE) after realignment - Stock Titan
RARE Shareholder Alert: Ultragenyx Pharmaceutical Inc. - GlobeNewswire
2026-03-27 | RARE SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Ultragenyx Pharmaceutical Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit! | NDAQ:RARE | Press Release - Stockhouse
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Ultragenyx Pharmaceutical Inc. of Class Action Lawsuit and Upcoming DeadlinesRARE - PR Newswire
RARE SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds Ultragenyx Pharmaceutical (RARE) Investors of Securities Class Action Deadline on April 6, 2026 - marketscreener.com
Analysts Offer Insights on Healthcare Companies: Ultragenyx Pharmaceutical (RARE), TELA Bio (TELA) and Nuvalent (NUVL) - The Globe and Mail
Ultragenyx Pharmaceutical (NASDAQ:RARE) Upgraded to "Strong-Buy" at Truist Financial - MarketBeat
RARE Deadline: RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit - Lelezard
Ultragenyx Pharmaceutical Stock Hits Day Low of $18.29 Amid Price Pressure - Markets Mojo
Ultragenyx Pharmaceutical Hits Day Low at $19.86 Amid Price Pressure - Markets Mojo
Ultragenyx Pharmaceutical Hits 52-Week Low at $18.29 Amidst Declining Performance - Markets Mojo
Lost Money on Ultragenyx Pharmaceutical Inc.(RARE)? Join Class A - GuruFocus
Ultragenyx Shareholder Alert: ClaimsFiler Reminds Investors - GlobeNewswire
Ultragenyx Pharmaceutical Inc Azioni (RARE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Ultragenyx Pharmaceutical Inc Azioni (RARE) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Parschauer Karah Herdman | EVP and Chief Legal Officer |
Mar 10 '26 |
Sale |
22.67 |
3,508 |
79,526 |
66,820 |
1.44%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):